Global Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market, By Drug (Elvitegravir, Cabotegravir, Raltegravir, Dolutegravir, Other), Application (HIV Infection, Occupational Exposure, Pre-Exposure Prophylaxis), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intramuscular, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In the first-line therapy of human immunodeficiency virus type 1 (HIV-1) infection, integrase strand transfer inhibitors (INSTIs) are now suggested. The first-generation INSTIs are successful, but they have the potential to select for virus resistance. Several potent second-generation INSTIs have recently been developed that are effective against both wild-type (WT) HIV-1 integrase and several of the first-generation INSTI-resistant mutations. Because resistance to these new second-generation INSTIs has been negligible, other treatment techniques for HIV-1 patients have been developed. INSTIs will also likely play a key role in pre-exposure prophylaxis due to their high antiviral potencies and, in some cases, bioavailability profiles (PrEP).
Data Bridge Market Research analyses that the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market was valued at USD 761.5 million in 2021 and is expected to reach USD 1232.16 million by 2029, registering a CAGR of 6.20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug (Elvitegravir, Cabotegravir, Raltegravir, Dolutegravir, Other), Application (HIV Infection, Occupational Exposure, Pre-Exposure Prophylaxis), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intramuscular, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Gilead Sciences, Inc. (US), Emcure Pharmaceuticals Limited. (India), Cipla Inc. (US), Hetero (India), Bausch Health Companies Inc. (Canada), Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Biocon (India), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Shanghai Desano Pharmaceuticals Co., Ltd. (China), Laurus Labs (India), Ipca Laboratories Ltd. (India), Flamingo Pharma Limited (India)
|
|
Market Opportunities
|
|
Market Definition
Integrase strand transfer inhibitors stop integrase, a human immunodeficiency virus Type 1 (HIV-1) viral enzyme involved in integrating viral DNA into the host chromosome, from working. For viral replication to take place, the viral DNA must be integrated into the host DNA. Integrase strand transfer inhibitors are used to prevent the human immunodeficiency virus from reproducing in the host and are not a cure for HIV or AIDS.
Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Dynamics
Drivers
- Increasing prevalence of human immunodeficiency virus (HIV)
The rising prevalence of human immunodeficiency virus (HIV) is anticipated to influence the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market's growth. Bictegravir (BIC), elvitegravir (EVG), dolutegravir (DTG) and raltegravir (RAL) are four integrase strand transfer inhibitors (INSTIs) that have been licensed for use in antiretroviral therapy (ART)-naive HIV patients. Cabotegravir (CAB) is a novel INSTI that has been authorized for use in combination with rilpivirine (RPV) in a long-acting injectable comprehensive antiretroviral (ARV) regimen to replace a stable oral regimen in patients with viral suppression.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market. Additionally, side effects of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI) market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI) market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.
Global Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Scope
The human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Elvitegravir
- Cabotegravir
- Raltegravir
- Dolutegravir
- Other
Application
- HIV Infection
- Occupational Exposure
- Pre-Exposure Prophylaxis
Dosage
- Injection
- Tablet
- Others
Route of Administration
- Oral
- Intramuscular
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Regional Analysis/Insights
The human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market is analysed and market size insights and trends are provided by country, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market because of the rising prevalence of human immunodeficiency virus type 1 in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Human Immunodeficiency Virus (HIV) Integrase Strand Transfer Inhibitors (INSTI) Market Share Analysis
The human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market.
Some of the major players operating in the human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI)? market are:
- Gilead Sciences, Inc. (US)
- Emcure Pharmaceuticals Limited. (India)
- Cipla Inc. (US)
- Hetero (India)
- Bausch Health Companies Inc. (Canada)
- Johnson & Johnson Private Limited (US)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Biocon (India)
- Bristol-Myers Squibb Company (US)
- GlaxoSmithKline plc (UK)
- Shanghai Desano Pharmaceuticals Co., Ltd. (China)
- Laurus Labs (India)
- Ipca Laboratories Ltd. (India)
- Flamingo Pharma Limited (India)
SKU-